ライフサイエンスコーパス: embolism

1 ymptomatic deep vein thrombosis or pulmonary embolism).

2 events (deep venous thrombosis or pulmonary embolism).

3 y of 0.90 (95% CIs: 0.78-1.00) for pulmonary embolism.

4 s not suggest routine use in acute pulmonary embolism.

5 gency department to rule out acute pulmonary embolism.

6 lation in a porcine model of acute pulmonary embolism.

7 mate 2.3% among survivors of acute pulmonary embolism.

8 events, deep vein thrombosis, and pulmonary embolism.

9 esult in bidirectional shunt and paradoxical embolism.

10 [CI], 0.04 to 1.2); no patient had pulmonary embolism.

11 of the 105 patients (16.2%) had a pulmonary embolism.

12 ssociated deep vein thrombosis and pulmonary embolism.

13 ) to decrease the risk of stroke or systemic embolism.

14 s not indicated to safely rule out pulmonary embolism.

15 of human DVT associated with fatal pulmonary embolism.

16 ic attack, or extracranial systemic arterial embolism.

17 mptomatic leaves are not associated with air embolism.

18 ion and those at risk of recurrent pulmonary embolism.

19 egarding hemocompatibility and potential for embolism.

20 its ability to recover from drought-induced embolism.

21 nd function in patients with acute pulmonary embolism.

22 mbolysis for submassive or massive pulmonary embolism.

23 stroke, deep vein thrombosis, and pulmonary embolism.

24 er ratio in massive and submassive pulmonary embolism.

25 g from incompletely resolved acute pulmonary embolism.

26 reventing deep vein thrombosis and pulmonary embolism.

27 without contrast media to rule out pulmonary embolism.

28 scans, 78 (9.8%) were positive for pulmonary embolism.

29 s a composite of ischemic stroke or systemic embolism.

30 ncy department for suspected acute pulmonary embolism.

31 in UK BioBank, most strongly with pulmonary embolism.

32 butions are shaped by their vulnerability to embolism.

33 a, cardiogenic pulmonary edema and pulmonary embolisms.

34 patient who died (relative risk of pulmonary embolism, 0; 95% CI, 0.00 to 0.55).

35 CrI 1.78-2.89, p<0.0001) and fatal pulmonary embolism (1.58, 1.14-2.19, p=0.01), but less major bleed

36 ansient ischemic attack [TIA]: 32%, systemic embolism: 1%).

37 5% of patients in either group was pulmonary embolism (13 [6%] vs seven [3%]).

38 ociated with a lower occurrence of pulmonary embolism (2/18; 11%) than standard regimen (11/22, 50%-o

39 ipients had a higher rate of stroke/systemic embolism (20.0% versus 8.7%, adjusted OR: 2.46, 95% CI:

40 19 have an increased prevalence of pulmonary embolisms (26%), and most (78.7%) have moderate or sever

41 Six patients with pulmonary embolism (46%) and 14 patients without pulmonary embolis

42 P = 0.001), and increased rate of pulmonary embolism (5.4% vs 0.9%, P = 0.007) in comparison to NSQI

43 lism (46%) and 14 patients without pulmonary embolism (52%) died at ICU discharge (odds ratio 0.79 [0

44 is Procedure for Intermediate-Risk Pulmonary Embolism; 8 mg/2 hours, 8 mg/4 hours, 12 mg/6 hours, and

45 f this study was the occurrence of pulmonary embolism according to the use of standard thromboprophyl

46 mong individuals aged 15-55 years, pulmonary embolism accounted for 8-13 per 1000 deaths in women and

47 eatment of critical limb ischemia, pulmonary embolism, acute ischemic stroke, and acute aortic syndro

48 lications including development of pulmonary embolism, acute respiratory distress syndrome, systemic

49 Amniotic fluid embolism (AFE) remains one of the principal reported cau

50 for the efficacy outcomes of stroke/systemic embolism, all-cause death, or myocardial infarction was

51 nce of deep vein thrombosis alone, pulmonary embolism alone.

52 Both scores successfully exclude pulmonary embolism, although YEARS has a better negative predictiv

53 CI, 0.62-0.70) for ischemic stroke/systemic embolism and 0.69 (95% CI, 0.66-0.71) for major bleeding

54 ductance (g(s) ), net assimilation (A), vein embolism and abscisic acid (ABA) concentration during de

55 were evaluated at baseline, after pulmonary embolism and after each dose by biventricular pressure-v

56 aluated in vivo at baseline, after pulmonary embolism and after each dose by invasive hemodynamic mea

57 patients had submassive or massive pulmonary embolism and an RV/LV diameter ratio >=0.9 on chest comp

58 wer rate of both ischemic stroke or systemic embolism and bleeding compared with those prescribed riv

59 shed risk factor for VTEs, such as pulmonary embolism and deep vein thrombosis.

60 thromboembolism (VTE), composed of pulmonary embolism and deep venous thrombosis, is a significant ca

61 coagulant agents are favored for cardiogenic embolism and highly thrombophilic conditions.

62 I 0.00-1.76]), but the results for pulmonary embolism and major bleeding are highly uncertain.

63 rediction model for ischemic stroke/systemic embolism and major bleeding in patients with atrial fibr

64 The results of the pulmonary embolism and major bleeding meta-analyses are uncertain

65 Five-year risks for ischemic stroke/systemic embolism and major bleeding were estimated without antic

66 and safety outcomes were stroke or systemic embolism and major bleeding.

67 events occurred during the study (pulmonary embolism and myocarditis while taking amantadine, and a

68 bopag group: one treatment-related pulmonary embolism and one vertigo.

69 em status (e.g. leaf water potential, native embolism and safety margin) on >150 trees from 12 genera

70 n a porcine in vivo model of acute pulmonary embolism and vasorelaxation in isolated pulmonary arteri

71 The location of pulmonary embolisms and the degree of elevation of D-dimer levels

72 early ischaemic events (stroke/TIA/systemic embolism) and d-sICH.

73 schaemic event (stroke/TIA/systemic arterial embolism) and delayed symptomatic intracranial haemorrha

74 estine perforation, pneumonia, and pulmonary embolism) and two (1%) in the lenalidomide and dexametha

75 etect drought-induced xylem blockages (e.g., embolisms) and quantify corresponding declines in sap fl

76 emodynamically unstable with acute pulmonary embolism, and a minority of them have proximal limb-thre

77 failure hospitalization, stroke or systemic embolism, and all-cause mortality.

78 ined source and indirect evidence of cardiac embolism, and in the prevention of vascular-mediated cog

79 int, and pulmonary embolism, fatal pulmonary embolism, and major bleeding as secondary endpoints.

80 is (symptomatic and asymptomatic), pulmonary embolism, and major bleeding.

81 otoxicosis, alcohol, pericarditis, pulmonary embolism, and myocarditis).

82 group and one unknown causes, one pulmonary embolism, and one lymphoma in the dolutegravir group); n

83 two patients (15.4%) had isolated pulmonary embolism, and one patient (7.7%) had both cannula-associ

84 infarction, deep vein thrombosis, pulmonary embolism, and pneumonia).

85 ons, such as deep vein thrombosis, pulmonary embolism, and stroke.

86 fficient in water transport and resistant to embolism, and therefore a hydraulic efficiency-safety tr

87 0-G in increasing risk for stroke, pulmonary embolism, and venous thromboembolism through its effect

88 estimates of the burden imposed by pulmonary embolism are not available to this date.

89 nduits were embolized, and substantial xylem embolism arose only under severe dehydration.

90 Our results implicate xylem embolism as a driver of leaf mortality during drought.

91 ography is associated with a similar risk of embolism as that detected by both LGE CMR and echocardio

92 p-vein thrombosis, hemoptysis, and pulmonary embolism as the most likely diagnosis) and measured the

93 We compared the rates of stroke/systemic embolism at 1 year according to diabetes status (no diab

94 econdary end point was symptomatic pulmonary embolism between day 8 and day 90 in the subgroup of pat

95 es done in patients with suspected pulmonary embolisms between March 15 and April 30, 2020 and compar

96 D-dimer levels or the location of pulmonary embolisms between the two groups.

97 includes deep vein thrombosis and pulmonary embolism), but the evidence is uncertain.

98 We quantified the degree of xylem embolism by combining in vivo x-ray microtomography with

99 etter understand the etiopathogenesis of fat embolism by comparing the lipid composition of lungs pos

100 mically stable patients with acute pulmonary embolism can be safely managed as outpatients.

101 stroke, transient ischemic attack, systemic embolism, cardiovascular death, major or nonmajor clinic

102 ry efficacy of composite of stroke, systemic embolism, cardiovascular/unexplained death, and safety).

103 ous thrombosis (DVT) and secondary pulmonary embolism cause approximately 100,000 deaths per year in

104 Pulmonary embolism caused a four-fold increase in pulmonary vascul

105 CC embolism causes arterial obstructions and organ failure

106 o large-artery atherosclerosis (LAA), cardio-embolism (CE), small-vessel occlusion (SVO), other deter

107 Deep vein thrombosis and pulmonary embolism, collectively defined as venous thromboembolism

108 ex" (these end points plus stroke, pulmonary embolism, colorectal cancer, and hip fracture) during th

109 as 6.4% in those with subsegmental pulmonary embolism compared with 6.0% in those with more proximal

110 with a 4-fold higher long-term incidence of embolism compared with matched non-LV thrombus patients.

111 ary noncardiac conditions, such as pulmonary embolism, critical illness, and sepsis, probably cause m

112 , stroke, surgical site infection, pulmonary embolism, deep venous thrombosis, and death.

113 ere observed for interventions for pulmonary embolism/deep vein thrombosis (A 0%, B 24%, C 76%), infe

114 icity than CT angiography alone in pulmonary embolism detection.

115 lation within 7 days after injury, pulmonary embolism developed in none of those in the vena cava fil

116 t is concluded that stomatal closure was not embolism-driven, but, rather, that onset of stomatal clo

117 group of patients at low risk for pulmonary embolism during follow-up.

118 solutions between vessel cells and restricts embolisms during drought.

119 Deep Vein Thrombosis and pulmonary embolism (DVT/PE) is one of the most common causes of un

120 ability remains unclear, as does the role of embolism events in signaling drought stress.

121 rtality as a primary endpoint, and pulmonary embolism, fatal pulmonary embolism, and major bleeding a

122 e model of acute intermediate-risk pulmonary embolism, fluid loading increased right ventricular prel

123 pletely halted recovery from drought-induced embolism for up to 24 h after re-irrigation, while parti

124 While these processes do not affect embolism formation during stress, they may prime stems f

125 eaf death across the canopy, to test whether embolism formation in the xylem during drought drives th

126 y and damage are spatially coordinated, with embolism formation occurring from the inside out and ref

127 t the xylem of both species was resistant to embolism formation, with 50% of embolized xylem area occ

128 ional adjustments occurs at the same time as embolism formation.

129 creased AE events were not a result of xylem embolism formation.

130 ibe early occurrence and severity of gaseous embolism (GE) and DCS in marine turtles after incidental

131 ssociated with a high incidence of pulmonary embolisms, generally peripherally distributed and associ

132 All patients in whom pulmonary embolism had not been ruled out underwent CT pulmonary a

133 r relative risks (RR) of stroke and systemic embolism, hemorrhagic stroke, myocardial infarction, car

134 0.349-0.783, P = 0.002) and not in pulmonary embolism (HR 0.882; 95% CI 0.511-1.521, P = 0.651).

135 ls resulting from the presence of nongaseous embolisms (i.e. tyloses and gels) than control leaves, b

136 ation of Disease-10 code for acute pulmonary embolism (I26) or any code for deep or superficial vein

137 CTPA was positive for pulmonary embolism in 16 of 60 (26.7%).

138 o Prevent Deep Vein Thrombosis and Pulmonary Embolism in 2008 has been lower than expected given the

139 years, CHA(2)DS(2)-VASc = 4.4 +/- 1.0, prior embolism in 48%.

140 ion in water potential at which 50% of total embolism in a tissue is observed (P(50) ) was explained

141 herapy for the prevention of stroke/systemic embolism in patients with atrial fibrillation.

142 h warfarin for prevention of stroke/systemic embolism in patients with atrial fibrillation.

143 outcomes of incidentally detected pulmonary embolism in patients with cancer.

144 Risk factors for pulmonary embolism in patients with coronavirus disease 2019 inclu

145 ts (VKAs) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillati

146 dabigatran, for reducing stroke and systemic embolism in patients with nonvalvular atrial fibrillatio

147 vention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undet

148 Diagnosis of pulmonary embolism in pregnancy is challenging, with symptoms of p

149 gnostic pathways for evaluation of pulmonary embolism in pregnancy that show conflicting recommendati

150 ed by guidelines for evaluation of pulmonary embolism in pregnancy, reviews current evidence, compare

151 formed decision making to diagnose pulmonary embolism in pregnancy.

152 , and higher, but variable, levels of native embolism in the branches.

153 tended to attribute the decline of Kleaf to embolism in the leaf vein xylem.

154 stomatal closure preceded the appearance of embolism in the leaves and the stem by several days.

155 aging widely used for diagnosis of pulmonary embolism in the non-pregnant population show limitations

156 The prevalence of pulmonary embolisms in the same period in 2019 was 13.2%, similar

157 y to move water due to drought-induced xylem embolism - in a pine sapling experiment.

158 Pulmonary embolism increased mean pulmonary arterial pressure (p <

159 who did not receive a diagnosis of pulmonary embolism initially and did not receive anticoagulant the

160 h, myocardial infarction, stroke or systemic embolism, intracranial bleeding, major bleeding, and hos

161 Xylem cavitation resulting in air embolism is a major cause of plant death during drought,

162 ing supports the hypothesis that paradoxical embolism is an important mechanism of ischemic stroke in

163 ients, whereas a strategy in which pulmonary embolism is considered to be ruled out with a low C-PTP

164 Pulmonary embolism is incidentally diagnosed in up to 5% of patien

165 ydraulic damage caused by elevated levels of embolism is likely to be one of the key drivers of droug

166 Pulmonary embolism is one of the leading causes of maternal death

167 Pregnancy-associated pulmonary embolism is one of the leading causes of maternal mortal

168 etrospective analyses suggest that pulmonary embolism is ruled out by a d-dimer level of less than 10

169 g in pregnant women with suspected pulmonary embolism is unknown.

170 es both deep venous thrombosis and pulmonary embolism, is a common and potentially fatal condition.

171 includes deep vein thrombosis and pulmonary embolism, is a common complication of cancer and is asso

172 n the diagnostic approach to acute pulmonary embolism, it has a major role in the evaluation of patie

173 Compared with directly measured midday embolism levels, the PAD and AI methods substantially ov

174 adacitinib 30 mg), one adjudicated pulmonary embolism (<1%; upadacitinib 15 mg), and one death (<1%;

175 751) were at higher risk for stroke/systemic embolism, major bleeding, and all-cause death than the s

176 suggest that prevention of DVT and pulmonary embolism may be improved by mechanical devices specifica

177 atients with more life-threatening pulmonary embolism may derive the greatest benefit from ultrasound

178 y is challenging, with symptoms of pulmonary embolism mimicking those of pregnancy.

179 in a collagen/epinephrine-induced pulmonary embolism model of in vivo platelet activation relative t

180 organ dysfunction syndrome (n=2), pulmonary embolism (n=2), sepsis (n=1), and small intestine perfor

181 p (death, febrile neutropenia, and pulmonary embolism [n=2 each]; enterocolitis, general physical hea

182 vein thrombosis network, 12 in the pulmonary embolism network (13 interventions; n=15 555), and 19 in

183 e, 28-35 days) ranked first in the pulmonary embolism network (RR 0.02 [95% CrI 0.00-3.86]) and LMWH

184 Concerning fat embolism, non-significant differences could be establish

185 ed and evaluated, of whom 7.4% had pulmonary embolism on initial diagnostic testing.

186 Venous thromboembolism (pulmonary embolism or any lower-limb deep-vein thrombosis) occurre

187 n a lower incidence of symptomatic pulmonary embolism or death at 90 days than no placement of a filt

188 int was a composite of symptomatic pulmonary embolism or death from any cause at 90 days after enroll

189 na cava filter reduces the risk of pulmonary embolism or death in severely injured patients who have

190 tly lower incidence of symptomatic pulmonary embolism or death than no placement of a filter (13.9% i

191 s defined as deep vein thrombosis, pulmonary embolism, or both, diagnosed greater than 24 hours after

192 or proximal deep-vein thrombosis, pulmonary embolism, or venous thromboembolism-related death during

193 dose in the reductions in stroke or systemic embolism (p interaction = 0.26), major bleeding (p inter

194 c species had surprisingly low resistance to embolism (P(50) ) and negative safety margins.

195 draulic conductivity, vulnerability to xylem embolism (P(50) ) and the turgor loss point (P(tlp) ).

196 em conductivity (K(s) ), xylem resistance to embolism (P50), sapwood allocation relative to leaf area

197 and optimal therapy for incidental pulmonary embolism, particularly distal clots, is unclear.

198 low-up within 1 y in patients with pulmonary embolism (PE) and the factors predictive of complete or

199 fee-for-service beneficiaries with pulmonary embolism (PE) between 1999 and 2015 to assess changes ac

200 Asthma and pulmonary embolism (PE) can present with overlapping symptoms, and

201 the EMR to automatically classify Pulmonary Embolism (PE) cases.

202 imaging modality for diagnosis of pulmonary embolism (PE) could be influenced by provider, patient o

203 Intermediate-risk (submassive) pulmonary embolism (PE) describes normotensive patients with evide

204 The prevalence of pulmonary embolism (PE) in patients presenting with syncope to the

205 ed rates of diagnostic testing for pulmonary embolism (PE) in US emergency departments (EDs), and no

206 Pulmonary embolism (PE) is a leading cause of maternal mortality,

207 Pulmonary embolism (PE) is a potentially fatal cardiopulmonary dis

208 Pulmonary embolism (PE) is a serious and prevalent cause of vascul

209 Acute pulmonary embolism (PE) is associated with high morbidity and mort

210 Pulmonary embolism (PE) is associated with increased risk for isch

211 Pulmonary embolism (PE) represents the third leading cause of card

212 CT iodine maps are used to detect pulmonary embolism (PE) with CT angiography but require dedicated

213 des deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of vascula

214 ients with acute intermediate-risk pulmonary embolism (PE).

215 tication, cardiac arrest caused by pulmonary embolism, postresuscitation oxygenation and ventilation,

216 ng optical light transmission, we visualized embolism propagation in grapevine (Vitis vinifera) and r

217 t material-enhanced CT angiography pulmonary embolism protocol and cardiac MRI were performed for fur

218 t material-enhanced CT angiography pulmonary embolism protocol and cardiac MRI were performed for fur

219 sed patients with acute submassive pulmonary embolism randomly assigned to 1 of 4 tPA dosing regimens

220 imity to the sugars within the phloem to the embolism recovery process.

221 ation between conductivity and resistance to embolism, rejecting a hardwired trade-off for this pair

222 013 and 2015, an average of 38 929 pulmonary embolism-related deaths occurred annually in the 41 Memb

223 Deaths were considered pulmonary embolism-related if International Classification of Dise

224 We aimed to assess pulmonary embolism-related mortality and time trends in the WHO Eu

225 The observed decreasing trends in pulmonary embolism-related mortality might reflect improved manage

226 and 2015, age-standardised annual pulmonary embolism-related mortality rates decreased linearly from

227 or studying extreme dehydration recovery and embolism repair in the petioles of intact plants.

228 l infarction, ischemic stroke, and pulmonary embolism, represent an important source of adverse outco

229 Stem embolism resistance and leaf turgor loss point appear to

230 aulic conductance (K(shoot) ) and stem xylem embolism resistance in Selaginella haematodes and S. pul

231 High embolism resistance in the curiously overbuilt New Zeala

232 Embolism resistance is the most useful predictor of the

233 s in HSF during the 2015-ENSO, greater xylem embolism resistance maintained similar hydraulic safety

234 ulic traits (e.g. hydraulic conductivity and embolism resistance) and plant hydraulic system status (

235 We propose that embolism-resistant xylem and large capacitance, provided

236 tients with cancer with incidental pulmonary embolism, risk of recurrent venous thromboembolism is si

237 atients in control groups had more pulmonary embolism (RR 2.22, 95% CrI 1.78-2.89, p<0.0001) and fata

238 Patients with subsegmental pulmonary embolism seemed to have a risk of recurrent venous throm

239 hat in xylem networks with low connectivity, embolism spread between conduits leading to multiple con

240 Knowledge of embolism spread will help us to uncover the links betwee

241 esting a link between vessel arrangement and embolism spread.

242 is to evaluate rates of stroke and systemic embolism (SSE) in patients with cardiovascular implantab

243 Pulmonary embolism still imposes a relevant medical and societal b

244 o underwent PFO closure due to a cryptogenic embolism (stroke: 76%, transient ischemic attack [TIA]:

245 ator, acute myocardial infarction, pulmonary embolism, stroke/transient ischemic attack, intracranial

246 h 6.0% in those with more proximal pulmonary embolism (subdistribution hazard ratio, 1.1; 95% CI, 0.3

247 p-vein thrombosis in a lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper l

248 nt stroke/transient ischemic attack/systemic embolism, symptomatic intracerebral hemorrhage (sICH), a

249 nables to unravel the pathogenesis of the CC embolism syndrome as a basis for both prophylaxis and ta

250 specialists differ in their vulnerability to embolism that would make water transport difficult durin

251 ch is caused by hydraulic failure due to air embolism, the pathogen itself, and/or plant-derived tylo

252 To evaluate the frequency of acute pulmonary embolism, the use of clinical probability scores, and th

253 , febrile neutropenia (five [6%]), pulmonary embolism (three [4%]), bronchitis (two [2%]), atrial fib

254 The authors hypothesized that paradoxical embolism through patent foramen ovale (PFO) should be th

255 essure threshold that would initiate runaway embolism throughout the entire experiment.

256 lant death during drought, yet the spread of embolism throughout the plant water transport system is

257 op a new animal model of cholesterol crystal embolism to dissect the molecular mechanisms of choleste

258 e proximal deep-vein thrombosis or pulmonary embolism to receive oral apixaban (at a dose of 10 mg tw

259 nd Activase for Treatment of Acute Pulmonary Embolism) to identify clinical characteristics that inde

260 bophlebitis, deep vein thrombosis, pulmonary embolism, transitory ischemic attacks to arteritis.

261 all pregnant women with suspected pulmonary embolism undergo computed tomographic (CT) pulmonary ang

262 Risk stratification for acute pulmonary embolism using imaging presence of right ventricular dys

263 (stroke, transient ischemic attack, systemic embolism, valve thrombosis, or hospitalization for heart

264 Vulnerability to embolism varies between con-generic species distributed

265 coronary artery dissection, coronary artery embolism, vasospasm, myocardial bridging and stress-indu

266 ably explained by a combination of pulmonary embolism, ventilation-perfusion mismatching in the nonin

267 nically ventilated patients have a pulmonary embolism visible on CT pulmonary angiography.

268 We quantified the variation in stem embolism vulnerability and leaf turgor loss point among

269 The frequency of acute pulmonary embolism was 23.0% and the Wells Score was explicitly us

270 ncidence rate of ischemic stroke or systemic embolism was 6.6 per 1000 person-years for adults prescr

271 ormed a prospective study in which pulmonary embolism was considered to be ruled out without further

272 Pulmonary embolism was diagnosed in 20 patients (4.0%) at baseline

273 A pulmonary embolism was found in three patients (23.1%).

274 Survival after pulmonary embolism was increased in diabetic DKO mice relative to

275 Acute pulmonary embolism was induced by administration of three large au

276 Pulmonary embolism was induced by jugular vein infusion of (125)I-

277 Acute pulmonary embolism was induced by large emboli made from clotting

278 If pulmonary embolism was not diagnosed, patients did not receive ant

279 The cumulative incidence of embolism was not different in patients with LV thrombus

280 Pulmonary embolism was ruled out if none of the three criteria wer

281 Pulmonary embolism was safely ruled out by the pregnancy-adapted Y

282 up of 3.3 years, the cumulative incidence of embolism was significantly higher in LV thrombus patient

283 sm was not suspected before death; pulmonary embolism was the direct cause of death in 4 patients.

284 The prevalence of pulmonary embolisms was higher in patients with COVID-19 (26% vs.

285 ving pregnant women with suspected pulmonary embolism, we assessed three criteria from the YEARS algo

286 d a recent diagnosis of incidental pulmonary embolism were eligible.

287 ssive (n=31) or submassive (n=119) pulmonary embolism were enrolled.

288 Leaf, stem and root xylem vulnerability to embolism were measured with the single vessel injection

289 ) and VTE (deep vein thrombosis or pulmonary embolism) were assessed.

290 lts for all endpoints except fatal pulmonary embolism, where evidence of an effect was weaker (1.42,

291 D and AI methods substantially overestimated embolism, whereas the BD, MicroCT and OP methods provide

292 One of these pathologies is fat embolism, which has been described histologically in the

293 as found between depth, risk and severity of embolism, which has not been previously demonstrated in

294 interleaf variability in xylem resistance to embolism, which may act as a buffer against complete can

295 n patients (33%) were diagnosed of pulmonary embolism, which was bilateral in six patients and locali

296 oembolism (deep vein thrombosis or pulmonary embolism) who were new users of apixaban or rivaroxaban

297 risk reduction for ischemic stroke/systemic embolism with dabigatran 150 mg twice daily ranged from

298 rial cancer with tamoxifen and one pulmonary embolism with placebo.

299 interleaf variability in xylem resistance to embolism, with a 1.45 MPa variation in the water potenti

300 had transient ST-segment elevation from air-embolism, without sequelae.